- Home
- PCSA vs WLDS Comparison
PCSA vs WLDS Comparison
Compare PCSA & WLDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- WLDS
- Stock Information
- Founded
- PCSA 2011
- WLDS 2014
- Country
- PCSA United States
- WLDS Israel
- Employees
- PCSA N/A
- WLDS N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- WLDS Computer Communications Equipment
- Sector
- PCSA Health Care
- WLDS Telecommunications
- Exchange
- PCSA Nasdaq
- WLDS Nasdaq
- Market Cap
- PCSA 3.3M
- WLDS 3.8M
- IPO Year
- PCSA N/A
- WLDS 2022
- Fundamental
- Price
- PCSA $0.22
- WLDS $1.11
- Analyst Decision
- PCSA Strong Buy
- WLDS
- Analyst Count
- PCSA 1
- WLDS 0
- Target Price
- PCSA $2.00
- WLDS N/A
- AVG Volume (30 Days)
- PCSA 6.1M
- WLDS 1.2M
- Earning Date
- PCSA 08-05-2025
- WLDS 01-01-0001
- Dividend Yield
- PCSA N/A
- WLDS N/A
- EPS Growth
- PCSA N/A
- WLDS N/A
- EPS
- PCSA N/A
- WLDS N/A
- Revenue
- PCSA N/A
- WLDS $522,000.00
- Revenue This Year
- PCSA N/A
- WLDS N/A
- Revenue Next Year
- PCSA N/A
- WLDS N/A
- P/E Ratio
- PCSA N/A
- WLDS N/A
- Revenue Growth
- PCSA N/A
- WLDS 536.59
- 52 Week Low
- PCSA $0.15
- WLDS $1.05
- 52 Week High
- PCSA $1.58
- WLDS $38.80
- Technical
- Relative Strength Index (RSI)
- PCSA 45.18
- WLDS 32.49
- Support Level
- PCSA $0.20
- WLDS $1.05
- Resistance Level
- PCSA $0.24
- WLDS $1.93
- Average True Range (ATR)
- PCSA 0.02
- WLDS 0.17
- MACD
- PCSA 0.00
- WLDS -0.06
- Stochastic Oscillator
- PCSA 30.82
- WLDS 6.82
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About WLDS Wearable Devices Ltd.
Wearable Devices Ltd develops and sells human-machine interface solutions for the smart wearables industry. These digital devices include consumer electronics, smart watches, smartphones, AR glasses, VR headsets, televisions, PCs, laptop computers, drones, robots, etc. The company has completed the transition phase from research and development to commercialization of technology into B2B and B2C products. Its products include Mudra Inspire, a band for the Apple Watch that allows touchless operation and control of Apple ecosystem devices such as iPhone, Mac computer, Apple TV, and iPad, inter alia.